Business Context and Reporting Period
Cognition Therapeutics, Inc. (CGTX), an emerging growth company incorporated in Delaware, filed this Form 8-K on May 7, 2026. The filing serves to announce the financial results for the quarter ended March 31, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were released in a separate press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide data to compare current period performance against prior comparable periods. No specific material changes in financial condition or operations are detailed within this document.
Guidance, Outlook, and Risks
The filing does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific Q1 2026 financial figures.
- Verify the company's cash runway and burn rate, as these are critical for pre-revenue or early-stage biotech firms.
- Confirm the status of clinical trials and regulatory milestones mentioned in the press release.
- Check for any dilutive financing activities or debt covenants triggered by the reported results.